You are here: Industry Insights > DiscGenics

News List

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone prnasia
April 27, 2021
DiscGenics, Inc. today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of chronic low back pain.
DiscGenics treates First Patients in Japanese Clinical Trial of Cell Therapy for DDD biospectrumasia
August 08, 2019
The prospective, randomized, double-blinded, sham-controlled study is designed to evaluate the safety and preliminary efficacy of IDCT at two dosage levels in subjects with single-level, symptomatic lumbar DDD, a major cause of chronic low back pain
DiscGenics Announces First Patient Treated in U.S. Trial of IDCT for Degenerative Disc Disease americanpharmaceuticalreview
April 27, 2018
DiscGenics announced the first patient has been treated in its phase I/II U.S. clinical trial of IDCT for mild-to-moderate degenerative disc disease (DDD).